Cargando…

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Patients with triple-negative breast cancer (TNBC) suffer an unfavorable prognosis. Carboplatin (CBDCA) as a cytotoxic reagent has been widely administered to patients with cancer including TNBC. Programmed cell death protein 1 (PD-1) is an immune checkpoint, blockade of which unleashes T cell funct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Meizhuo, Wang, Tie, Ji, Litong, Bai, Shuping, Tian, Lining, Song, Hongjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066228/ https://www.ncbi.nlm.nih.gov/pubmed/32194569 http://dx.doi.org/10.3389/fimmu.2020.00366

Ejemplares similares

Roxatidine inhibits fibrosis by inhibiting NF-κB and MAPK signaling in macrophages sensing breast implant surface materials
por: Ji, Litong, et al.
Publicado: (2020)

Interleukin (IL)-4 -590C>T polymorphism is not associated with the susceptibility of gastric cancer: An updated meta-analysis
por: Wang, Tie, et al.
Publicado: (2016)

Macrophages on the Peritoneum are involved in Gastric Cancer Peritoneal Metastasis
por: Song, Hongjiang, et al.
Publicado: (2019)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

Evaluation of carboplatin sustained‐release delivery system in dogs with cancer
por: Tansey Baldwin, Colleen, et al.
Publicado: (2016)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
por: Cheung, Anthony, et al.
Publicado: (2022)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
por: Shakir, Abdur R.
Publicado: (2014)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
por: Wu, Rongrong, et al.
Publicado: (2021)

Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer
por: Marcheteau, Elie, et al.
Publicado: (2021)

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells
por: Wang, Yi, et al.
Publicado: (2022)

One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer
por: Steenbrugge, Jonas, et al.
Publicado: (2022)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
por: de Moraes, Francisco Cezar Aquino, et al.
Publicado: (2023)

Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis
por: Jin, Guixiu, et al.
Publicado: (2013)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer
por: Abreu de Oliveira, Willy Antoni, et al.
Publicado: (2021)

Multiple Analytical Approaches Demonstrate a Complex Relationship of Genetic and Nongenetic Factors with Cisplatin- and Carboplatin-Induced Nephrotoxicity in Lung Cancer Patients
por: Liu, H. Eugene, et al.
Publicado: (2014)

Seizure and delirium secondary to carboplatin and pantoprazole therapy‐induced hypomagnesemia in a cancer patient
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
por: Liu, Lingyue, et al.
Publicado: (2022)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Sustained Release of an Anti-Glaucoma Drug: Demonstration of Efficacy of a Liposomal Formulation in the Rabbit Eye
por: Natarajan, Jayaganesh V., et al.
Publicado: (2011)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Zheng, Xin, et al.
Publicado: (2021)

Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
por: Kim, Hyeyoon, et al.
Publicado: (2022)

Autoimmune Encephalitis Associated with Anti-N-methyl-D-aspartate Receptor and Anti-Hu Antibodies Successfully Treated with Carboplatin and Etoposide for Small-cell Lung Cancer
por: Shobatake, Ryogo, et al.
Publicado: (2022)

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
por: Huang, Renhong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_58hv65g7ofb45luclvl4esnv32